Who is sponsoring NCT02242318?

NCT02242318 is sponsored by Boehringer Ingelheim.

What condition does NCT02242318 study?

NCT02242318 studies Hypertension.

What drugs are being tested in NCT02242318?

Interventions: Telmisartan, Valsartan, Placebo.

What is the status of NCT02242318?

NCT02242318 is currently COMPLETED.

Last reviewed 2014-09-16 · How we verify

A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

NCT02242318 Phase 4 COMPLETED

The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over 24 hours), and to compare telmisartan 80 mg to valsartan 160 mg in lowering DBP during the last six hours of the dosing interval at the end of a 6 to 8-week treatment period, as measured by ABPM (change from baseline)

Details

Lead sponsor	Boehringer Ingelheim
Phase	Phase 4
Status	COMPLETED
Enrolment	440
Start date	2001-09

Conditions

Hypertension

Interventions

Telmisartan
Valsartan
Placebo

Primary outcomes

Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose — Baseline, Day 41, Day 55
measured by ambulatory blood pressure monitoring (ABPM)
Change in mean DBP during the last 6 hours of the 24 hour dosing interval — up to 8 weeks